CSI Market
Sign In | Register

Ernexa Therapeutics Inc (ERNA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ERNA quarterly Cash Flow →
This page allows investors to follow Ernexa Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-14.08
Depreciation & amortization0.07
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Goodwill, Impairment Loss0.03
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Other Assets0.01
Share-based Compensation1.64
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.77
Excess And Obsolete Site Equipment To Be Installed Expense-
Transfer Of Fixed Assets To Salestype Lease-
Capitalized Computer Software Impairments-
Amortization Of Operating Lease Rightofuse Assets-
Scrap Expense-
Increase Decrease Site Equipment To Be Installed-
Depriciation And Amortization-
Modification Of Vested Restricted Common Shares Expense-
Operating Lease Right Of Use Asset Amortization Expense0.20
Noncash Merger Related Costs-
Increase Decrease In Deposit Assets And Other Non Current Assets-
Gain Loss On Disposal Of Fixed Assets-
Commitment Shares Issue Expense-
Commitment Shares Issued Expense-
Fair Value Adjustments To Bridge Notes Derivative Liability-
Interest Expense Debt0.02
Increase Decrease In Operating Lease Liability-
Gain Loss On Change In Fair Value Of Contingent Consideration-
Income taxes0.00
Equity Method Investment, Realized Gain (Loss) on Disposal0.00
Increase (Decrease) in Due from Related Parties-0.41
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.06
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.27
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities6.46
Discontinued operations0.00
Net Cash flow from Operating Activities-7.02
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Indefinite Lived Intangible Assets Period Increase Decrease-
Proceeds From Sales Of Securities Availableforsale-
Acquisition Costs-
Changes In Restricted Cash-
Payments To Acquire Productive Assets Net-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.04
Financing Activities
Short-term debt Net2.25
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.96
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Rights Offering Net-
Tax Withholding Related To Netshare Settlements Of Restricted Stock Units-
Payments To Cashedout Stockholders In Connection With Reverse-
Adjustment To Common Stock In Connection With Reverseforward Stock Split-
Adjustments To Common Stock In Connection With Reverseforward Stock Split Note-
Tax Withholding Payments For Net Share Settlement Of Vested Restricted Stock Units-
Initial Measurement Of Operating Lease Rightofuse Assets And Liabilities-
Site Equipment Transferred To Fixed Assets-
Equipment Acquired Under Capital Lease-
Finance Lease Principal Payments-
Payments Of Paycheck Protection Program Loan-
Proceeds From Sale Of Members Equity-
Proceeds From Issuance Of Common Stock To Lincoln Park-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.21
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.05
Total Cash Flow0.16
4 historic quarters locked

Sign in to unlock the full Ernexa Therapeutics Inc cash flow history.

Sign In Create Free Account

About Ernexa Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 13, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-010102

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License